Literature DB >> 743965

Electrophoretically separable forms of rat prolactin with different bioassay and radioimmunoassay activities.

H Asawaroengchai, S M Russell, C S Nicoll.   

Abstract

The possible existence of forms of rat PRL with different bioassay (BA)/RIA activity ratios was investigated. Anterior pituitary tissue and medium in which explants of rat adenohypophyses had been incubated were processed by polyacrylamide disc gel electrophoresis using a Tris-glycine buffer. The gel columns were cut into five segments and eluates from these were tested for PRL by BA and by RIA. Most of the BA- and RIA-detectable PRL in tissue and medium was found in the same gel region to which purified rat PRL (RP-1) migrated. The BA/RIA ratio of this major form of PRL was 2.2-4.0. Other more slowly migrating forms of PRL were found in the regions where albumin and growth hormone migrate. The BA/RIA activity ratios of these forms varied depending on the sample processed (e.g., tissue vs. medium; sex and/or age of the adenohypophyseal donor; duration of incubation) but were generally considerably higher than those of the respective major forms. PRL that migrated faster than the major form was also detected by the RIA in several cases, but in only one experiment (with 4-day culture medium) was bioassayable PRL present in this more anodal region. In this case the BA/RIA ratio was very high (78.6). These results indicate that forms of rat PRL with different BA/RIA activity ratios exist within and are secreted by rat adenohypophyses.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 743965     DOI: 10.1210/endo-102-2-407

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  10 in total

Review 1.  Paradigm-shifters: phosphorylated prolactin and short prolactin receptors.

Authors:  KuangTzu Huang; Eric Ueda; YenHao Chen; Ameae M Walker
Journal:  J Mammary Gland Biol Neoplasia       Date:  2008-01-25       Impact factor: 2.673

2.  Isolation and partial characterization of a pair of prolactins released in vitro by the pituitary of a cichlid fish, Oreochromis mossambicus.

Authors:  J L Specker; D S King; R S Nishioka; K Shirahata; K Yamaguchi; H A Bern
Journal:  Proc Natl Acad Sci U S A       Date:  1985-11       Impact factor: 11.205

3.  Glycosylated ovine prolactin.

Authors:  U J Lewis; R N Singh; L J Lewis; B K Seavey; Y N Sinha
Journal:  Proc Natl Acad Sci U S A       Date:  1984-01       Impact factor: 11.205

Review 4.  Cleavage of prolactin by its target organs and the possible significance of this process.

Authors:  C S Nicoll
Journal:  J Mammary Gland Biol Neoplasia       Date:  1997-01       Impact factor: 2.673

5.  Bioactivity and immunoreactivity of rat pituitary prolactin submitted to various extraction procedures.

Authors:  M I Prada; H A Pasolli; A I Torres; A Aoki
Journal:  J Endocrinol Invest       Date:  1995-05       Impact factor: 4.256

6.  Isolation and characterization of phosphorylated bovine prolactin.

Authors:  B G Kim; C L Brooks
Journal:  Biochem J       Date:  1993-11-15       Impact factor: 3.857

7.  Isolation of cleaved prolactin variants that stimulate DNA synthesis in specific cell types in rat pituitary cell aggregates in culture.

Authors:  M Andries; D Tilemans; C Denef
Journal:  Biochem J       Date:  1992-01-15       Impact factor: 3.857

8.  Major metabolic pathways and hormone production in unstimulated monolayer cultures of the rat anterior pituitary.

Authors:  G Rappay; I Nagy; G B Makara; E Bácsy; I N Fazekas; M Kárteszi; M Kurcz
Journal:  In Vitro       Date:  1979-10

Review 9.  Prolactin receptor antagonists.

Authors:  C B Kuo; D Coss; A M Walker
Journal:  Endocrine       Date:  1998-10       Impact factor: 3.925

10.  Prolactin Variants in Human Pituitaries and Pituitary Adenomas Identified With Two-Dimensional Gel Electrophoresis and Mass Spectrometry.

Authors:  Shehua Qian; Yongmei Yang; Na Li; Tingting Cheng; Xiaowei Wang; Jianping Liu; Xuejun Li; Dominic M Desiderio; Xianquan Zhan
Journal:  Front Endocrinol (Lausanne)       Date:  2018-08-28       Impact factor: 5.555

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.